1. Home
  2. BEAM vs SBCF Comparison

BEAM vs SBCF Comparison

Compare BEAM & SBCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$26.87

Market Cap

2.6B

Sector

Health Care

ML Signal

N/A

Logo Seacoast Banking Corporation of Florida

SBCF

Seacoast Banking Corporation of Florida

N/A

Current Price

$33.01

Market Cap

3.1B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
BEAM
SBCF
Founded
2017
1926
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
3.1B
IPO Year
2019
2009

Fundamental Metrics

Financial Performance
Metric
BEAM
SBCF
Price
$26.87
$33.01
Analyst Decision
Strong Buy
Hold
Analyst Count
15
6
Target Price
★ $49.38
$36.46
AVG Volume (30 Days)
★ 1.8M
844.3K
Earning Date
11-10-2026
10-27-2026
Dividend Yield
N/A
★ 2.41%
EPS Growth
★ 82.31
10.56
EPS
N/A
★ 0.84
Revenue
★ $24,000.00
N/A
Revenue This Year
N/A
$29.59
Revenue Next Year
$14.48
$5.98
P/E Ratio
★ N/A
$39.49
Revenue Growth
★ 33.33
N/A
52 Week Low
$20.23
$28.69
52 Week High
$38.26
$36.27

Technical Indicators

Market Signals
Indicator
BEAM
SBCF
Relative Strength Index (RSI) 55.77 50.62
Support Level $25.29 $32.83
Resistance Level $28.87 $34.73
Average True Range (ATR) 1.47 0.78
MACD 0.47 0.13
Stochastic Oscillator 55.38 47.64

Price Performance

Historical Comparison
BEAM
SBCF

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About SBCF Seacoast Banking Corporation of Florida

Seacoast Banking Corp of Florida is a holding company. The company provides integrated financial services, including commercial and consumer banking, wealth management, and mortgage and insurance services, to customers across Florida through branch, mobile, and online banking solutions. It maintains day-to-day operations, particularly in the areas of operations, treasury management systems, information technology, and security. The company has one reportable segment that provides these integrated financial services, with segment revenues driven mainly by interest and fees on loans, interest on cash and cash equivalents, and investment securities, and fees on depository products and services.

Share on Social Networks: